Sensorium Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Sensorium Therapeutics, Inc. - overview
Established
2021
Location
Boston, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and founded in 2021 by its CEO Dick Simon, and co-founders Jacob Hooker, Jerry Rosenbaum, and Steve Haggarty, Sensorium Therapeutics, Inc. operates as a biotechnology company that focuses on the research and development of medical drugs for treating mental health illnesses. In August 2025, Sensorium Therapeutics, Inc. raised USD 25 million in Series A funding from investors Dolby Family Ventures, Hatteras Venture Partners, Mission Biocapital, and Mockingbird Credit Partners, with participation from investors CU Healthcare Innovation Fund, Harris Barton Asset Management, Route 66 Ventures, Iter Investments, Ocama Partners, Palo Santo Venture Fund, re.
Mind Capital, WPSS. bio, and Sante Ventures. Sensorium Therapeutics, Inc. offers a biodynamic discovery platform that leverages cutting-edge chemistry, neuroscience, and machine learning to identify, reproduce, adapt, and enhance targeted molecules and elevates their utility as modern medicines that can deliver transformational benefits to patients.
In addition, the company is also developing SENS-01 as a rapid-acting and well-tolerated therapeutic for patients with anxiety and depression. The company plans to use the series A funding to increase its workforce and to further develop its business. The company will use the August 2025 funding to test a new medicine made from a succulent plant to see if it helps people feel less anxious.
Current Investors
Sante Ventures, Route 66 Ventures, CU Healthcare Innovation Fund
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Bioinformatics, Mental Health Services, Medical Software
Website
www.sensorium.bio
Verticals
Artificial Intelligence, HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.